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Abstract: BACKGROUND AND AIMS Loss-of-function variants in protein tyrosine phosphatase non-
receptor type-2 (PTPN2) promote susceptibility to inflammatory bowel diseases (IBD). PTPN2 regulates
Janus-kinase (JAK) and signal transducer and activator of transcription (STAT) signaling, while pro-
tecting the intestinal epithelium from inflammation-induced barrier disruption. The pan-JAK inhibitor,
tofacitinib, is approved to treat ulcerative colitis but its effects on intestinal epithelial cell-macrophage
interactions and on barrier properties are unknown. We aimed to determine if tofacitinib can rescue
disrupted epithelial-macrophage interaction and barrier function upon loss of PTPN2. METHODS Hu-
man Caco-2BBe intestinal epithelial cells (IECs) and THP-1 macrophages expressing control or PTPN2-
specific shRNA were co-cultured with tofacitinib or vehicle. Transepithelial electrical resistance and 4
kDa fluorescein-dextran flux were measured to assess barrier function. Ptpn2fl/fl and Ptpn2-LysMCre
mice, which lack Ptpn2 in myeloid cells, were treated orally with tofacitinib citrate twice daily to assess
the in vivo effect on the intestinal epithelial barrier. Colitis was induced via administration of 1.5% DSS
in drinking water. RESULTS Tofacitinib corrected compromised barrier function upon PTPN2 loss in
macrophages and/or IECs via normalization of (i) tight junction protein expression, (ii) excessive STAT3
signaling, and (iii) IL-6 and IL-22 secretion. In Ptpn2-LysMCre mice, tofacitinib reduced colonic pro-
inflammatory macrophages, corrected underlying permeability, and prevented the increased susceptibility
to DSS colitis. CONCLUSIONS PTPN2 loss in IECs or macrophages compromises IEC-macrophage in-
teractions and reduces epithelial barrier integrity. Both of these events were corrected by tofacitinib in
vitro and in vivo. Tofacitinib may have greater therapeutic efficacy in IBD patients harboring PTPN2
loss-of-function mutations.
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ABSTRACT (max 250 words) 19	
Background and Aims: Loss-of-function variants in protein tyrosine phosphatase non-receptor 20	
type-2 (PTPN2) promote susceptibility to inflammatory bowel diseases (IBD). PTPN2 regulates 21	
Janus-kinase (JAK) and signal transducer and activator of transcription (STAT) signaling, while 22	
protecting the intestinal epithelium from inflammation-induced barrier disruption. The pan-JAK 23	
inhibitor, tofacitinib, is approved to treat ulcerative colitis but its effects on intestinal epithelial 24	
cell–macrophage interactions and on barrier properties are unknown. We aimed to determine if 25	
tofacitinib can rescue disrupted epithelial-macrophage interaction and barrier function upon loss 26	
of PTPN2. 27	
Methods: Human Caco-2BBe intestinal epithelial cells (IECs) and THP-1 macrophages 28	
expressing control or PTPN2-specific shRNA were co-cultured with tofacitinib or vehicle. 29	
Transepithelial electrical resistance and 4 kDa fluorescein-dextran flux were measured to assess 30	
barrier function. Ptpn2
fl/fl
 and Ptpn2-LysMCre mice, which lack Ptpn2 in myeloid cells, were 31	
treated orally with tofacitinib citrate twice daily to assess the in vivo effect on the intestinal 32	
epithelial barrier. Colitis was induced via administration of 1.5% DSS in drinking water. 33	
Results: Tofacitinib corrected compromised barrier function upon PTPN2 loss in macrophages 34	
and/or IECs via normalization of (i) tight junction protein expression, (ii) excessive STAT3 35	
signaling, and (iii) IL-6 and IL-22 secretion. In Ptpn2-LysMCre mice, tofacitinib reduced 36	
colonic pro-inflammatory macrophages, corrected underlying permeability, and prevented the 37	
increased susceptibility to DSS colitis. 38	
Conclusions: PTPN2 loss in IECs or macrophages compromises IEC-macrophage interactions 39	
and reduces epithelial barrier integrity. Both of these events were corrected by tofacitinib in vitro 40	
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and in vivo. Tofacitinib may have greater therapeutic efficacy in IBD patients harboring PTPN2 41	
loss-of-function mutations. 42	
 43	
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 Inflammatory bowel diseases (IBD) are chronic inflammatory conditions of the digestive 59	
tract, which manifest as diarrhea, abdominal pain, ulcers, and in severe cases, anemia and 60	
micronutrient deficiency. IBD encompasses ulcerative colitis (UC) and Crohn’s disease (CD), 61	
which differ in their histopathology and the affected intestinal regions.
1-3
 IBD is multi-factorial, 62	
with genetic, environmental, immunological and microbial factors contributing to disease 63	
manifestation.
4
 Due to the complex pathogenesis of IBD, most current therapeutic strategies 64	
alleviate IBD symptoms, rather than target specific disease-driving molecular pathways.
5,6
 65	
Biologics, such as anti-TNF treatment emerged as an effective treatment for IBD, but 30-50% of 66	
patients lose clinical response to anti-TNF treatment,
7,8
 partially due to production of anti-drug 67	
antibodies,
9
 thus alternative treatment strategies are being developed and/or tested for use in 68	
IBD.  69	
Tofacitinib (Xeljanz®) is a small-molecule pan-Janus kinase (JAK) inhibitor approved 70	
for the treatment of moderate-to-severe ulcerative colitis. JAK family molecules are mediators of 71	
pro-inflammatory cytokine signaling, and tofacitinib has proven effective in treating chronic 72	
diseases, including IBD.
10-13
 However, only 40.6% of UC patients showed sustained clinical 73	
remission under tofacitinib treatment thus indicating that only a proportion of patients are 74	
responsive.
12
 While pre-clinical animal studies have investigated the effects of tofacitinib on 75	
models of intestinal inflammation, studies of specific cell types in the gut (i.e. intestinal 76	
epithelial cells and macrophages) targeted by tofacitinib are limited in number.
14-16
  77	
 The barrier function of the intestinal epithelium ensures separation of luminal contents 78	
from underlying tissues while allowing regulated passage of fluid and electrolytes. Tight 79	
junctions, which consist of several transmembrane proteins, selectively seal the paracellular 80	
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space between intestinal epithelial cells (IECs) and control the passage of water and ions.
17,18
 81	
Epithelial barrier disruption allows bacteria and bacterial components to penetrate the epithelium 82	
and to initiate immune responses, which in turn have detrimental effects on the tight junction 83	
complex.
19
 Increased intestinal permeability is an early feature of IBD
20
 that precedes intestinal 84	
inflammation and is a prognostic factor for relapse in Crohn’s disease.
21-25
 Moreover, a recent 85	
prospective study of a large cohort of asymptomatic first-degree relatives of IBD patients 86	
identified that increased intestinal permeability is significantly associated with increased future 87	
risk of developing Crohn’s disease, and thus represents a separate pre-disease risk factor for later 88	
onset of Crohn’s disease independent of potential subclinical inflammation
26
.  89	
Over 240 single-nucleotide polymorphisms (SNP) have been associated with increased 90	
risk for IBD, including protein tyrosine phosphatase non-receptor type 2 (PTPN2), which 91	
encodes the T cell protein tyrosine phosphatase (TCPTP).
4,27-30
 IBD-associated single nucleotide 92	
polymorphisms (SNPs) within the PTPN2 gene locus have been reported to result in decreased 93	
PTPN2 expression
31
 and TCPTP phosphatase activity
32
, while a recent report showed that a loss-94	
of-function mutation in the phosphatase domain encoding region of PTPN2 results in loss of 95	
TCPTP activity and very early onset intestinal inflammation 
33
. The most studied PTPN2 96	
variants in the context of IBD are SNP rs1893217 and SNP rs2542151. These two SNPs are in 97	
linkage disequilibrium
32
 and have a minor allele frequency of approximately 16% in the general 98	
population and 20% in IBD patients
27
, although geographic regional differences exist
27
. 99	
Substrates of TCPTP include members of the JAK-signal transducer and activator of 100	




 mice exhibit intestinal 101	
inflammation and succumb to systemic inflammation between 3-5 weeks of age.
37
 Knockdown 102	
of PTPN2 in human IEC cultures promotes STAT activation and enhances barrier defects in the 103	
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presence of the pro-inflammatory cytokine IFN-γ.38 In a model of naïve T cell transfer-mediated 104	
colitis, RAG2 knockout mice injected with Ptpn2-deficient T cells showed increased STAT1 and 105	
STAT3 levels.
39
 Further, Ptpn2-LysMCre mice, which lack TCPTP primarily in macrophages 106	
and monocytes, are more susceptible to acute DSS-induced colitis.
40
 Recently, we have shown 107	
that TCPTP loss in macrophages affects IEC properties (i.e. barrier function), and in turn, 108	
TCPTP-deficient IECs alter macrophage functions and cytokine secretion
41
. Further, JAK-109	
inhibition by tofacitinib reduced IFN-γ-induced barrier dysfunction in IEC lines and human 110	
colon organoids through modulation of tight junction molecules.
42
 Here, we translate earlier 111	
findings in individual cell types to relevant co-culture and in vivo models to show that tofacitinib 112	
directly affects IEC and macrophage cell function. Moreover, tofacitinib also corrects defects in 113	
the interactions between these cell types, culminating in increased intestinal permeability, that 114	
arise from TCPTP deficiency and elevated JAK-STAT signaling.	 	115	
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MATERIALS AND METHODS 116	
Cell culture 117	
 Human Caco-2BBe intestinal epithelial cells (IECs) were cultured in Dulbecco’s 118	
Modification of Eagle’s Medium (DMEM, #15-017-CV, Corning, Corning,	NY) supplemented 119	
with 10% heat-inactivated fetal bovine serum (Thermo Fisher Scientific, Waltham, MA) and 1% 120	
L-glutamine (Lonza, 17-605E, Walkersville, MD). Human THP-1 cells were cultured in RPMI 121	
1640 medium (#10-040-CV, Thermo Fisher Scientific) with 10% heat-inactivated fetal bovine 122	
serum (Thermo Fisher Scientific). All cells were grown in standard 12-well cell culture plates 123	
(#130185, ThermoScientific, Rochester, NY) or transwell membranes (#3460, Corning, 124	
Kennebunk, ME) in a humidified incubator at 37°C with 5% CO2. 125	
 126	
Generating stable shRNA PTPN2-deficient cell lines 127	
 Cell lines stably expressing PTPN2 shRNA were generated as previously described.
43,44
 128	
Briefly, Caco-2BBe and THP-1 cells were infected with lentiviral constructs containing either 129	
PTPN2-specific, or non-targeting scrambled shRNA. After 72 h of infection, stable cell lines 130	
were selected using puromycin (400-128P, Gemini, New York, NY). Stable Caco-2BBe and 131	
THP-1 control (Ctr) and PTPN2 knockdown (KD) cell lines were maintained at 4 µg/mL and 0.5 132	





Measurement of transepithelial electrical resistance and 4 kDa FITC-dextran permeability in 136	
vitro 137	
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 Transepithelial electrical resistance (TEER) of Caco-2BBe cells grown on transwells was 138	
measured using an EVOM2 Epithelial Voltohmmeter (World Precision Instruments, Sarasota, 139	
FL). Values from an empty well were subtracted, and readings multiplied by the transwell 140	
surface area and expressed as Ohmscm
2
. After measurement of TEER, cells were washed twice 141	
and equilibrated in 1X PBS with CaCl2 and MgCl2 (D8662, Sigma-Aldrich, St. Louis, MO) for 142	
30 min at 37°C. Fluorescein isothiocynate (FITC)-4 kDa dextran (FD4, 1mg/ml, Sigma-Aldrich) 143	
was added to the apical side, and after 2 h at 37°C, fluorescence of duplicate samples from the 144	
basolateral medium was measured using a microplate reader (Promega, Madison, WI). FD4 145	
concentrations were calculated against a standard curve. 146	
 147	
Co-culture experiments and tofacitinib treatments in vitro 148	
 Caco-2BBe IECs were seeded on transwell membranes at 0.5 x 10
6
 cells per well and 149	
cultured for 8 days. Cells were then switched to serum-free media overnight before co-culture 150	
with THP-1 cells and/or treated with tofacitinib. Prior to co-cultures with IECs, 0.25 x 10
6
 THP-151	
1 monocytes were pulsed for 3 h with PMA (Sigma-Aldrich) to induce macrophage 152	
differentiation, seeded on 12-well standard cell culture plates for 48 h, and then switched to 153	
serum-free DMEM the day before the experiment. Prior to start of the co-culture, Caco-2BBe 154	
cells were pre-treated apically with vehicle (dimethyl sulfoxide, DMSO, 0.5%, Sigma-Aldrich) 155	
or tofacitinib (50 µM, MedChemExpress, Monmouth Junction, NJ) for 1 h followed by placing 156	
the transwells into the THP-1 cell-containing 12-well plates. After 24 h, TEER and FD4 157	
permeability were measured, the basolateral media collected, and protein from both Caco-2BBe 158	
and THP-1 cells harvested. 159	
 160	
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Harvesting and preparation of whole cell protein lysates 161	
 For protein isolation, cells were washed twice with ice-cold 1X PBS with CaCl2 and 162	
MgCl2 (D8662, Sigma-Aldrich) prior to lysis with RIPA lysis buffer (50 mM Tris-Cl pH 7.4, 150 163	
mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS) supplemented with 1X 164	
protease inhibitor (Roche, South San Francisco, CA), 2mM sodium fluoride, 2mM PMSF, and 165	
phosphatase inhibitors (2mM sodium orthovanadate, 1X Phosphatase Inhibitor Cocktail 2 and 3, 166	
Sigma-Aldrich) for 15 min at 4°C. Cells were scraped, transferred into microcentrifuge tubes and 167	
homogenized on ice using the Q125 Sonicator (QSonica Sonicators, Newtown, CT). Cell lysates 168	
were centrifuged at 16, 200 x g at 4°C for 10 min and the supernatants collected into new 169	
microcentrifuge tubes. Loading samples were prepared by mixing the same amount of total 170	
protein from each sample with Laemmli loading buffer (60 mM Tris-Cl pH 6.8, 2% SDS, 5% β-171	
mercaptoethanol, 0.01% bromophenol blue, and 10% glycerol), and boiling at 95°C for 10 min. 172	
 173	
Western blot 174	
 Proteins were separated by SDS-polyacrylamide gel electrophoresis, followed by transfer 175	
onto polyvinylidene difluoride membranes (EMD Millipore, Temecula, CA).  Membranes were 176	
blocked with 3% milk, 1% BSA in TBS-T (Tris-buffered saline with 0.1% Tween-20) for 1 h at 177	
room temperature, followed by overnight incubation with primary antibodies (see Supplementary 178	
Table 1) at 4°C overnight. The following day, membranes were rinsed with TBS-T (x3) then 179	
subjected to 5 min washes (x3) with TBS-T and then incubated with horseradish peroxidase-180	
conjugated goat anti-mouse or goat anti-rabbit IgG secondary antibodies (Supplementary Table 181	
1) in 3% milk, 1% BSA in TBS-T for 1 h at room temperature, and again washed with TBS-T 182	
(x3). Finally, membranes were incubated with SuperSignal
TM
 West Pico PLUS 183	
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Chemiluminescent Substrate solution (Thermo Fisher Scientific) and immunoreactive proteins 184	
were detected by exposing the membranes to X-ray film (LabScientific Inc., Highlands, NJ). 185	





 Caco-2 cells were grown on cover slides and cultured for 24 h with conditioned medium 189	
from macrophages as previously described
41
. Cells were washed 3 x in PBS, fixed in 100% 190	
methanol (20 min at -20°C), washed 3 x in PBS, permeabilized with Triton X (1% Triton X-100 191	
in PBS) for 30 min, washed 3 x in PBS containing 0.1% Tween (PBST), and incubated with 10% 192	
normal donkey serum in PBST for 1 h prior to incubation with anti ZO-1 antibody (1:200, 193	
Thermo Fisher Scientific) overnight at 4°C. Slides were washed three times with PBST, 194	
incubated with secondary antibody (anti-Rabbit AlexaFluor 488, 1:200, Jackson 195	
ImmunoResearch) for 1 h at room temperature, washed 3 x in PBST, and mounted using 196	
ProlongGold Antifade Reagent with DAPI (Thermo Fisher Scientific).  197	
For in vivo evaluation of tight junction molecules, OCT-embedded frozen sections were 198	
cut into 5 µm sections, slides brought to room temperature, rinsed 2 times with PBST, and fixed 199	
in methanol (10 min at -20°C). Slides were incubated in blocking buffer (PBS + 2% donkey 200	
serum, 1% BSA, 1% Triton X, 0.05% Tween-20) for 1 h prior to overnight incubation with F’ab 201	
donkey-anti-mouse antibody (Jackson ImmunoSearch Inc, West Grove, PA). The slides were 202	
rinsed with PBST, incubated with mouse-anti-claudin-2, rabbit anti-ZO-1 and goat anti-E-203	
cadherin antibody (all from Thermo Fisher Scientific, diluted in PBS + 5% normal donkey 204	
serum) for 30 minutes at room temperature, rinsed again with PBS prior to incubation with a 205	
biotinylated secondary anti-mouse antibody (Jackson ImmunoSearch Inc.) for 20 minutes 206	
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followed by an additional wash in PBST, and subsequent incubation with Alexa Fluor 488-207	
steptavidin, Alexa Fluor 647-anti-rabbit secondary antibody and Cy3-anti-goat secondary 208	
antibody (Jackson ImmunoSearch) for 30 minutes and finally mounted with ProlongGold 209	
Antifade Reagent with DAPI (Thermo Fisher Scientific). 210	
 211	
Mice  212	
 C57Bl/6 male and female mice homozygous for a floxed Ptpn2 gene and heterozygous 213	
for the LysMCre construct (Ptpn2-LysMCre mice, originally generated at the University 214	
Hospital Zurich, Zurich, Switzerland) and their LysMCre negative littermates (Ptpn2
fl/fl
 mice) 215	
were used for all studies.
40,46
 All animal experiments were conducted with approval from the 216	
Institutional Animal Care and Use Committee at the University of California, Riverside in 217	
accordance with the National Institute of Health guidelines for the use of live animals. 8-14 week 218	
old male and female mice housed in a specific pathogen-free (SPF) facility under a 12-h 219	
light/dark cycle and food/water ad libitum were used for all studies. 220	
 221	
Tofacitinib citrate treatment in vivo 222	
 Vehicle solution was prepared by dissolving methylcellulose (M7027, Sigma-Aldrich) at 223	
1% w/v in PBS.  Tofacitinib citrate gavage solution was prepared fresh every day by 224	
resuspending tofacitinib citrate powder (Selleckchem, Houston, TX) in vehicle solution. Gavage 225	
solutions were sonicated using the Q125 Sonicator (QSonica Sonicators) at 30% amplitude for 2 226	
min at 10 sec ON/OFF intervals at room temperature. Mice were orally gavaged with vehicle (5 227	
µL per g body weight) or tofacitinib citrate (50mg/kg body weight, in 5 µL per g body weight, 228	
concentration based on a previous study
14
) twice daily for 7 days (barrier measurements without 229	
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colitis induction) or 10 days (experiments with colitis induction). The amount of gavage solution 230	
was adjusted on a daily basis according to the weight of each individual and ranged from 80-120 231	
µL. 232	
 233	
Measurement of intestinal permeability in vivo 234	
 To assess barrier permeability in vivo, mice were food-deprived for 2 h prior to oral 235	
administration (200 µL) of gavage solution containing 100 mg/mL creatinine (#4255, Sigma-236	
Aldrich), 80 mg/mL FD4 (#46944, Sigma-Aldrich) and 20 mg/mL Rhodamine B-dextran 70kDa 237	
(RD70, #R9379, Sigma-Aldrich) dissolved in MilliQ H2O and filtered through a 0.2 µM syringe 238	
filter. A water-gavaged mouse was used as control. After 5 h, blood samples were collected and 239	
serum concentrations of the three probes determined as previously described
41,47
. At this point, 240	
animals were given access to food. 241	
 242	
Colitis induction 243	
 12-14 week old Ptpn2-LysMCre mice and their Ptpn2
fl/fl
 littermates were treated with 244	
tofacitinib citrate as described above for 10 days, starting three days prior to DSS exposure for 7 245	
days (1.5% in the drinking water; MP Biomedicals, Irvine, CA). Body weight and disease scores 246	
(based on activity level, stool consistency, weight loss, blood in stool scores) were recorded 247	
daily. At day 7 of DSS administration, the mice were euthanized, colon length measured, and the 248	
most distal 2 cm of the colon collected for histological assessment of colitis severity as described 249	
previously.
48
 The most distal section of the colon was used in order to assess the beneficial effect 250	




 Intestinal tissues were snap-frozen in liquid nitrogen for protein expression and ELISA 254	
analyses. To isolate IECs, proximal colons were everted and incubated in Cell Recovery Solution 255	
(#354253, Corning) on ice for 2 h then vigorously shaken to release IECs. IECs were washed 256	
twice with ice-cold PBS and proteins isolated as described above.  257	
 258	
Flow cytometry 259	
 After removal of IECs, intestinal tissues were cut into 0.5 cm pieces and digested with 260	
Collagenase type IV (0.6 mg/ml; Sigma-Aldrich, #C5138) for 15 min. Digested tissue pieces 261	
were then passed three times through a 18.5 G needle and homogenates filtered through a 7 µm 262	
cell strainer (BD Biosciences; Franklin Lakes, NJ). Cells were washed once with PBS before re-263	
suspension in 20 µL PBS containing Fc-receptor blocking antibodies for 10 min, before adding 264	
20 µL of fluorescence-labeled antibodies (see Supplementary Table 2) and incubation on ice for 265	
30 min. Samples were washed twice with ice-cold PBS, resuspended in 200 µL FACS buffer 266	
(PBS, 2% FBS) and acquired on an LSR-II flow cytometer from BD Biosciences. 267	
 268	
RNA isolation, RT-PCR, and quantitative PCR 269	
 Total RNA was isolated from whole proximal colons using RNeasy Mini Kit (Qiagen) 270	
per manufacturer’s directions. RNA concentration was measured by absorbance at 260 nm and 271	
280 nm using Nanodrop 2000c (Thermo Scientific, Rockford, IL) and reverse transcribed into 272	
complementary DNA (cDNA) using qScript cDNA SuperMix (Quantabio, Beverly, MA). qPCR 273	
was performed using iQ SYBR Green Supermix (Bio-Rad, Hercules, CA) and an IQ5 Real-Time 274	
PCR Thermal Cycler (Bio-Rad). Primers used for murine Il6, Il10, Il22, and Gapdh are listed in 275	
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Supplementary Table 3. Gene expression was calculated using the average CT values of triplicate 276	
readings normalized to the average of housekeeping gene Gapdh CT values. Gapdh was chosen 277	
as the housekeeping gene based on a previous evaluation of several housekeeping genes, where 278	
Gapdh was found most stable in our experimental settings (data not shown). Results were 279	
analyzed using the ΔΔCT method. 280	
 281	
Statistical Analysis 282	
 Data are presented as mean ± SD for n number of biological replicates. Animal data are 283	
presented as mean ± SD for one of two independent experiments, each with four to six mice as 284	
indicated in the figure legends. Statistical analysis was performed using ANOVA followed by 285	
Tukey’s or Holm-Sidak post-test. P values of ≤ 0.05 were considered significant. 286	
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RESULTS 287	
Tofacitinib corrects elevated permeability in IECs lacking PTPN2 and abrogates the effects of 288	
PTPN2-deficient macrophages on barrier function 289	
 To determine how macrophages influence IEC barrier function, and whether tofacitinib 290	
influences this cross-regulation, THP-1 cells were co-cultured with polarized Caco-2BBe cells 291	
that were treated with either vehicle or tofacitinib. As we have recently shown
41
, co-culture with 292	
control (Ctr) THP-1 macrophages tightened the epithelial barrier with increased TEER and 293	
reduced FD4 permeability, while co-culture with PTPN2 KD THP-1 cells resulted in a leaky 294	
barrier, i.e. reduced TEER and increased FD4 flux (Figure 1A+B). Treatment with tofacitinib for 295	
24 h, prevented both of these effects (Figure 1). As previously shown,
43,44
 TEER was 296	
significantly lower in resting PTPN2-deficient IECs compared to control IECs and co-culture 297	
with macrophages did not promote barrier tightness (i.e. no induction of TEER or reduced FD4 298	
flux), while co-culture with PTPN2 KD THP-1 further decreased TEER and increased FD4 299	
permeability in PTPN2-deficient IECs (Figure 1 and ref. 
41
). Of note, tofacitinib treatment 300	
completely abrogated these effects (Figure 1). Moreover, tofacitinib rescued the TEER of 301	
PTPN2-deficient Caco-2BBe cells to levels comparable to those of control Caco-2BBe cells 302	
(Figure 1A). These results show that the presence of control THP-1 macrophages induces 303	
tightening of the epithelial barrier while PTPN2-deficient macrophages promote paracellular 304	
passage of ions and macromolecules. Both of these effects on the IEC monolayer were abrogated 305	
by tofacitinib. These results demonstrate that JAK inhibition is sufficient to rescue the barrier 306	
defects observed in PTPN2-deficient IECs alone, or in IECs cultured in the presence of PTPN2-307	
deficient macrophages.  308	
 309	
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Tofacitinib prevents macrophage-induced changes in the expression of tight junction proteins  310	
 While the paracellular flux of macromolecules is mainly dictated by the presence and/or 311	
localization of tight junction proteins (e.g. occludin, tricellulin, JAM-A and ZO-1) the major 312	
influence on TEER, which fluctuates due to paracellular passage of ions, is mediated by changes 313	
in the charge- and size-selective family of claudin proteins.
49,50
 Consistent with previous 314	
findings
41
, and with the reduced TEER and increased macromolecular passage upon loss of 315	
TCPTP in macrophages and/or IECs, we observed increased expression of the pore-forming 316	
molecule claudin-2 and decreased expression of the barrier-sealing proteins junctional adhesion 317	
molecule (JAM-A), occludin, tricellulin, and claudin-4 in those cells. Consistent with the 318	
normalization of TEER, tofacitinib treatment normalized claudin-2 expression in co-culture 319	
groups and partly restored expression of claudin-4 in PTPN2 KD Caco2-BBe cells, though these 320	
still remained lower than control Caco2-BBe cells (Figure 2A, 2B, 2C). In addition, we observed 321	
molecule-specific changes in the expression of barrier-sealing proteins: while occludin and JAM-322	
A were both reduced in PTPN2-deficient IECs and in Ctr IECs co-cultured with PTPN2-323	
deficient macrophages, JAM-A but not occludin was further decreased upon loss of PTPN2 in 324	
both cell types. Notably, only the suppressive effect on occludin was rescued by tofacitinib, 325	
while tofacitinib treatment was not able to restore JAM-A levels. In contrast, tricellulin levels 326	
were only reduced when PTPN2 was absent in macrophages, and this effect was only rescued by 327	
tofacitinib treatment in Ctr IECs and not in PTPN2-deficient IECs (Figure 2A, 2D, 2F). Of note, 328	
while tofacitinib was able to normalize the expression of claudin-2 and occludin (Figure 2A, 2E), 329	
it also suppressed the induction of tricellulin and JAM-A observed upon co-culture with Ctr 330	
macrophages (Figure 2A, 2D, 2F). In addition to these changes in the expression of tight junction 331	
molecules, co-culture of Caco-2BBe cells with KD macrophages, or deletion of PTPN2 in Caco-332	
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2BBe cells also promoted internalization of the tight junction molecule ZO-1 and gap formation 333	
between neighboring IECs, effects completely normalized upon treatment with tofacitinib. 334	
TCPTP protein expression in IECs remained unchanged by co-culture with macrophages, 335	
tofacitinib treatment, or in combination (Figure 2A, 2G). Collectively, these results suggest that 336	
changes in the expression patterns of tight junction proteins are individual and distinct and that 337	
tofacitinib rescues the underlying barrier defect of PTPN2-deficient IECs, at least in part, 338	
through effects on claudin-2, claudin-4 and occludin. 339	
 340	
Elevated STAT1 and STAT3 phosphorylation in PTPN2-deficient IECs or macrophages are 341	
normalized by tofacitinib 342	
 TCPTP, the protein product of PTPN2, dephosphorylates several members of the JAK-343	
STAT signaling pathway, including JAK1 and JAK3 that are targeted by tofacitinib. Caco-2BBe 344	
cells lacking PTPN2 had significantly higher STAT1 and STAT3 phosphorylation (Figure 345	
3A+B), which were both effectively reduced upon treatment with tofacitinib for 24 h. These data 346	
show that tofacitinib can correct the elevated JAK-STAT activation in IECs with PTPN2 loss. 347	
Furthermore, co-culture with macrophages significantly increased STAT1 and STAT3 348	
phosphorylation in control Caco-2BBe, both of which were normalized upon tofacitinib 349	
treatment (Figure 3A+B).  350	
 Similarly, and consistent with findings among other PTPN2-deficient models, 351	
macrophages lacking PTPN2 had elevated JAK1 and STAT1 phosphorylation, which was further 352	
enhanced upon co-culture with either control or PTPN2-KD IECs, and again fully reversed by 353	
tofacitinib (Figure 4A+B). Co-culture of control THP-1 cells with PTPN2-deficient Caco-2BBe 354	
cells also induced JAK1 and STAT1 phosphorylation, and this was completely negated by 355	
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tofacitinib treatment (Figure 4A+B). STAT3 phosphorylation levels followed the same pattern in 356	
PTPN2-deficient macrophages, but in general, levels of phosphorylated STAT3 were rather low 357	
(Figure 4C). These results demonstrate that in control macrophages, JAK1 is activated in the 358	
presence of PTPN2-deficient IECs, but not in the presence of IECs that express normal PTPN2 359	
levels. However, co-culture with IECs of either genotype induced JAK1 and STAT1 360	
phosphorylation in both control and PTPN2-deficient THP-1 cells, though to a much larger 361	
extent in PTPN2 KD THP-1 cells, perhaps due to the elevated basal JAK1/STAT1 362	
phosphorylation. Overall, tofacitinib inhibited JAK-STAT signaling in macrophages co-cultured 363	
with IECs and reduced the significantly elevated level of JAK-STAT activation in PTPN2 KD 364	
macrophages to background levels.  365	
 366	
IL-6, IL-22, and TNF-α  secretion is induced by PTPN2 loss but corrected by tofacitinib  367	
 A major feature of IBD is altered cytokine secretion, and especially levels of the 368	
inflammatory cytokines TNF-α, IFN-γ and IL-6 as well as levels of IL-22 are highly increased, 369	
while the production or the response to the regulatory cytokine IL-10 is compromised in IBD 370	
patients.
51
 Co-culture of PTPN2-deficient macrophages with control Caco-2BBe cells resulted in 371	
secretion of IL-6, IL-22, and TNF-α, an effect further enhanced in PTPN2-deficient Caco-2BBe 372	
cells (Figure 4D, Supplementary Figure 1). Notably, tofacitinib treatment significantly reduced 373	
the robust increases in IL-6 and IL-22 (Figure 4D), suggesting that the aberrant secretion of IL-6 374	
and IL-22 upon loss of PTPN2 in IECs or macrophages may be due to elevated JAK signaling. 375	
Loss of PTPN2 in either cell type, however, had no statistically significant effect on IL-10 376	
secretion and was unaltered by tofacitinib treatment (Figure 4D). 377	
 378	
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Tofacitinib citrate corrected barrier dysfunction observed in Ptpn2-LysMCre mice in vivo 379	
 Building on our observations with in vitro co-culture models, we next determined 380	
whether the restoration of barrier function by tofacitinib translated to an in vivo setting using 381	
Ptpn2-LysMCre mice (lacking Ptpn2 primarily in monocytes and macrophages
40
) and their 382	
Ptpn2
fl/fl
 littermates. Consistent with previous findings
41
 Ptpn2-LysMCre mice exhibited higher 383	
in vivo FD4 permeability compared to their Ptpn2
fl/fl
 counterparts, which was substantially 384	
decreased upon twice daily gavage with tofacitinib citrate for 7 d (Figure 5A). In contrast, 385	
tofacitinib treatment had no significant effect on FD4 flux in Ptpn2
fl/fl
 animals (Figure 5A) 386	
suggesting no negative impact on the epithelial barrier upon tofacitinib treatment. Conversely, 387	
permeability to creatinine and RD70, which can detect effects on the paracellular pore or the 388	
unrestricted pathways, respectively, were not affected by genotype or tofacitinib citrate treatment 389	
(Figure 5B+C). Similar to our in vitro findings, these data suggest that intestinal permeability is 390	
elevated by PTPN2 loss in macrophages in vivo, and this effect can be corrected with JAK-391	
inhibition by tofacitinib. 392	
 393	
Tofacitinib rescues the molecular remodeling of tight junctions in IECs from Ptpn2-LysMCre 394	
mice  395	
  To delineate the mechanism behind changes in barrier function in vivo, the abundance of 396	
tight junction proteins in proximal colon IECs was analyzed. Consistent with previous findings
41
 397	
the expression of claudin-2 was significantly increased in IECs from Ptpn2-LysMCre mice 398	
(Figure 6A+B), while claudin-4, JAM-A, and occludin were all decreased when compared to 399	
Ptpn2
fl/fl
 controls (Figure 6A-E). These effects were corrected by tofacitinib citrate treatment, 400	
and expression patterns of these tight junction proteins were all reversed (Figure 6A-E). Of note 401	
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is the induction of occludin expression in Ptpn2
fl/fl
 mice by tofacitinib (Figure 6E), though this 402	
did not result in changes in FD4 permeability. In contrast, no changes in tricellulin expression 403	
were seen as a result of loss of Ptpn2 in macrophages or tofacitinib citrate treatment (Figure 6F). 404	
As described previously, and in line with our in vitro data, loss of Ptpn2 in macrophages 405	
promoted the expression of claudin-2 in the crypt regions of Ptpn2-LysMCre mice and resulted 406	
in reduced and more diffuse E-cadherin and ZO-1 staining (Figure 6G and Supplementary Figure 407	
2). These effects were normalized upon treatment with tofacitinib (Figure 6G and Supplementary 408	
Figure 2). 409	
 410	
STAT signaling is elevated in IECs of Ptpn2-LysMCre mice, which is effectively reduced by 411	
tofacitinib citrate administration 412	
 Similar to our cell culture data, Ptpn2-deficiency in macrophages also increased STAT3 413	
phosphorylation in IECs in vivo, an effect significantly reduced with tofacitinib citrate treatment 414	
(Figure 6H). Notably, TCPTP levels remained unchanged in IECs of Ptpn2
fl/fl
 vs. Ptpn2-415	
LysMCre mice and were unaffected by tofacitinib treatment (Figure 6I). IECs from Ptpn2-416	
LysMCre mice did not exhibit elevated STAT1 phosphorylation, suggesting that specific STAT 417	
family members are differentially regulated in these animals (Supplementary Figure 3).  418	
 419	
Gene and protein expression profiles of cytokines Il6, Il10, and Il22 in Ptpn2-LysMCre colons 420	
are reversed by tofacitinib citrate treatment 421	
 The local cytokine milieu critically influences epithelial and immune cell processes in the 422	
gut. To determine whether loss of Ptpn2 in macrophages affected the local cytokine milieu in the 423	




Ptpn2-LysMCre mice, treated with vehicle or tofacitinib citrate, were determined by qPCR 425	
(Figure 7A) and ELISA (Figure 7B). Il6/Il22 mRNA and IL-6/IL-22 protein expression were 426	
significantly elevated, while Il10 mRNA and IL-10 protein expression were decreased, in 427	
vehicle-treated Ptpn2-LysMCre mice compared to Ptpn2
fl/fl
 mice (Figure 7A+B). With 428	
tofacitinib citrate treatment, expression patterns of Il6/IL-6, Il10/IL-10, and Il22/IL-22 mRNA 429	
and protein levels were reversed, though differences in IL-10 protein expression between 430	
vehicle- and tofacitinib citrate-treated Ptpn2-LysMCre mice did not reach statistical significance 431	
(Figure 7A+B). 432	
 433	
Tofacitinib normalizes macrophage polarization profiles in Ptpn2-LysMCre mice  434	
 In line with these findings of altered cytokine production, increased proportions of M1 435	
macrophages were observed in Ptpn2-LysMCre mice compared to their Ptpn2
fl/fl
 counterparts, 436	
while M2 macrophage proportions were reduced, with no change in overall macrophage numbers 437	
(Figure 7C). Tofacitinib treatment had no effect on M1/M2 macrophage populations in Ptpn2
fl/fl
 438	
mice, but reversed the higher M1/lower M2 proportions in Ptpn2-LysMCre mice back to 439	
approximate ratios found in control mice (Figure 7C). These results confirm that loss of Ptpn2 440	
affects macrophage polarization, which can be normalized by tofacitinib administration. 441	
 442	
Barrier normalization by tofacitinib prevents increased susceptibility to DSS-induced colitis in 443	
Ptpn2-LysMCre mice 444	
 Finally, we assessed whether correction of barrier defects in Ptpn2-LysMCre mice using 445	
tofacitinib has consequences for the development of intestinal inflammation. Therefore, Ptpn2-446	
LysMCre mice were treated with tofacitinib starting 3 days prior to induction of colitis using 447	
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1.5% DSS. Pre-treatment with tofacitinib corrected the underlying increase in FD4 permeability 448	
in Ptpn2-LysMCre mice prior to the start of DSS administration (d0; Figure 8A). Moreover, 449	
tofacitinib pre-treatment prevented the DSS-induced increase in FD4 permeability in Ptpn2
fl/fl
 450	
and Ptpn2-LysMCre mice (d7; Figure 8A). Consistent with previous reports,
40
 vehicle-treated 451	
Ptpn2-LysMCre mice showed increased colitis severity, as measured by enhanced weight loss, 452	
increased disease activity scores, more pronounced shortening of the colon, and elevated 453	
histological colitis scores (Figure 8B-F). Notably, these effects were fully prevented by 454	
tofacitinib treatment (Figure 8B-D). Furthermore, tofacitinib administration starting 3 days prior 455	
to DSS administration also prevented the development of colitis in Ptpn2
fl/fl
 mice, as indicated by 456	
reduced histological colitis scores (Figure 8E+F).	 	457	
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DISCUSSION 458	
 In this study, we identified that tofacitinib corrects the disrupted homeostatic interaction 459	
between macrophages and intestinal epithelial cells lacking the IBD risk gene PTPN2. Our 460	
findings show that tofacitinib normalized barrier dysfunction and changes in tight junction 461	
protein expression following loss of PTPN2 in macrophages and IECs. This intestinal barrier-462	
rescuing effect of tofacitinib was confirmed in mice with myeloid cell-specific knockout of 463	
Ptpn2. These mice have an underlying, subclinical barrier defect, characterized by increased FD4 464	
permeability associated with reduced expression of tight junction-sealing proteins, elevated 465	
epithelial STAT3 activation, altered production of barrier modulating cytokines, increased levels 466	
of the pore-forming tight junction molecule claudin-2, and they are more susceptible to DSS-467	
induced colitis.
40
 All these effects were rescued upon treatment with tofacitinib. This 468	
demonstrates the clinical relevance of our findings and suggests that loss of functional PTPN2 in 469	
IBD patients, as observed in PTPN2 loss-of-function variant carriers,
32,52
 might render them 470	
more responsive to tofacitinib treatment. 471	
In agreement with previous data,
43
 PTPN2-deficient Caco-2BBe monolayers display 472	
much lower TEER and higher FD4 permeability compared to controls, and our data in Figure 1 473	
shows that tofacitinib rescues this effect. Here, we went a step further to demonstrate that 474	
tofacitinib rescues intestinal barrier defects caused by disruption of macrophage-IEC interactions 475	
upon loss of PTPN2 in either macrophages or IECs. In our co-culture studies, tofacitinib reversed 476	
the expression of some, but not all, tight junction proteins screened, implying that junctional 477	
proteins are differentially regulated by the presence of macrophages and/or JAK-STAT signaling 478	
in our co-culture system. In addition, since the effects of control and PTPN2-deficient THP-1 479	
cells on permeability of Caco-2BBe control monolayers were negated by tofacitinib treatment, 480	
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this suggests that tofacitinib-sensitive pathways (presumably JAK-driven) are involved in both 481	
the enhancing and detrimental effects of macrophages on IEC barrier function in vitro. Of note, 482	
there was no adverse effect of tofacitinib citrate treatment on the barrier function of Ptpn2
fl/fl
 483	
(wild-type) mice, which implies that in vivo, tofacitinib has no detrimental effect on intestinal 484	
permeability.	 485	
 STAT3 and STAT1 phosphorylation in Caco-2BBe cells correlated well with the changes 486	
seen in claudin-2 and occludin expression patterns. Disruption of the STAT-binding motif within 487	
the CLDN2 gene promoter prevents aberrantly high CLDN2 expression observed in PTPN2 KD 488	
IECs,
44
 and increased STAT3 activation in PTPN2-deficient IECs promotes claudin-2 489	
expression
41
. Whether occludin expression is regulated through JAK-STAT signaling is also not 490	
yet known. Surprisingly, the elevated expression of occludin in tofacitinib-treated Ptpn2
fl/fl
 mice 491	
did not yield a functional decrease in FD4 permeability in vivo. The net effect on occludin versus 492	
JAM-A (slightly decreased) and tricellulin (no change) expression may thus contribute to the 493	
lack of change in macromolecular permeability. 494	
 We observed profound changes in the cytokine profile upon loss of PTPN2/TCPTP in 495	
macrophages and/or epithelial cells, which were corrected by tofacitinib treatment. The strong 496	
upregulation of inflammatory cytokines (i.e. IL-6 and TNFα) is well in line with previous 497	
reports
53
 and indicates that TCPTP exerts a critical regulatory function on JAK/STAT signaling 498	
to maintain cytokine balance even in the absence of additional stimulation. In specific, we 499	
observed increased IL-6 secretion upon PTPN2 deletion in macrophages, IECs, and in 500	
combination. Notably, STAT3 is a major signaling transducer upon IL-6 receptor ligation,
54
 and 501	
represents a key downstream target of tofacitinib. Many of the observed effects downstream of 502	
PTPN2 loss can be explained by elevated IL-6 and increased STAT3 activation, but the overall 503	
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effect of IL-6 on epithelial barrier function is still under debate.
55
 While 72 h of IL-6 exposure 504	
has been shown to decrease TEER and increase mannitol permeability in Caco-2 monolayers,
56
 4 505	
kDa-dextran permeability was increased in IL-6 knockout mice when compared to controls,
57
 506	
Thus, IL-6 has pleiotropic functions and while some of the observed effects might result from 507	
elevated IL-6 in Ptpn2-LysMCre mice,
41
 there are likely other factors that contribute to the 508	
decreased TEER/barrier function upon loss of PTPN2 in IEC or macrophages. In line with this, 509	
we observed that the secretion pattern of TNF-α in our co-culture studies was similar to that of 510	
IL-6. TNF-α can induce IL-6 production in Caco-2 cells58 and, in combination with IFN-γ, in 511	
THP-1 cells,
59
 and thus might be responsible for the elevated IL-6 levels observed here. 512	
Epithelial and immune cells produce IL-6,
60
 therefore, the changes we observed in tight junction 513	
proteins and JAK-STAT activation could result from autocrine or paracrine signaling. In our co-514	
culture experiments, tofacitinib reduced IL-6 and TNF-α secretion, which agrees with recent 515	




 The profound changes in the expression profiles of IL-6, IL-22, and IL-10 upon loss of 518	
TCPTP, which were partially rescued upon tofacitinib treatment, yield insight into which 519	
mediators may be causing the changes observed in mice treated with tofacitinib citrate. The 520	
elevated expression of the pro-inflammatory cytokine IL-6 and reduced expression of anti-521	
inflammatory IL-10 in proximal colons of vehicle-treated Ptpn2-LysMCre mice suggest that at 522	
basal levels, the intestines of these mice are primed towards a pro-inflammatory phenotype. 523	
Furthermore, and in agreement with findings that IL-22 upregulates claudin-2 to increase water 524	
efflux for bacterial clearance,
47
 both IL-6 and IL-22 protein secretion and mRNA expression 525	






 and has been shown to promote epithelial restitution in wound-healing assays,
61
 and 527	
attenuate intestinal inflammation in vivo.
63
 528	
 Oral gavage of molecular probes such as FD4 and RD70, and assessment of their serum 529	
levels, allows for functional analysis of intestinal permeability in vivo.
47
 In this approach, 530	
unaltered permeability to RD70 confirmed the absence of mucosal damage in Ptpn2-LysMCre 531	
mice, while increased FD4 flux demonstrated an increase in the leak pathway, which allows 532	
smaller macromolecules, such as bacterial products, to pass through the epithelial paracellular 533	
barrier and elicit an immune response. Importantly, this effect was reversed upon tofacitinib 534	
citrate treatment, indicating that this drug can normalize barrier defects elicited by macrophages 535	
with a pro-inflammatory phenotype. Furthermore, and in agreement with a recent study 536	
demonstrating that tofacitinib pretreatment skews murine BMDMs towards a regulatory, M2-like 537	
phenotype,
14
 tofacitinib reversed the enhanced M1 macrophage levels in Ptpn2-LysMCre mice 538	
and restored M2 macrophage proportions. Together with our co-culture studies, this effect of 539	
tofacitinib on macrophage polarization indicates a novel mechanism by which JAK inhibition 540	
protects the intestinal epithelium. Of note, this protective effect on barrier permeability and 541	
correction of macrophage phenotype had direct consequences for the enhanced susceptibility to 542	
intestinal inflammation observed in Ptpn2-LysMCre mice, which was completely rescued upon 543	
tofacitinib administration. One notable difference from the De Vries study
14
 is that we observed 544	
inhibition of onset of DSS colitis symptoms by tofacitinib citrate pretreatment, albeit starting 3 545	
days prior to DSS vs. concurrent administration. Our results not only suggests that the 546	
detrimental effects of PTPN2-deficient macrophages on IEC barrier function is relevant for the 547	
development of intestinal inflammation, but also indicates that tofacitinib can restore barrier 548	
function and revert the enhanced colitis susceptibility of mice lacking PTPN2 in macrophages. 549	
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Moreover, the protective effect when administered prior to disease induction indicates that 550	
tofacitinib treatment might be a promising candidate to maintain remission in UC patients and 551	
especially in those with PTPN2 loss-of-function variants.  552	
 The genetic profiles of IBD patients included in tofacitinib clinical studies were not 553	
reported and thus it is still unknown whether genetic factors determine treatment success. Our 554	
results with macrophages and IECs lacking the IBD risk gene PTPN2, suggest that analyzing 555	
subgroups of patients with distinct genetic profiles for their response to tofacitinib might be a 556	
promising approach to detect patients that are more responsive for tofacitinib treatment. Adverse 557	
events such as increased rates of overall infections, herpes zoster infections, cardiovascular 558	
events, and increased serum lipid levels were observed in IBD patients who received tofacitinib 559	
treatment for 52 weeks,
12
 and higher rates of pulmonary embolisms and mortality have occurred 560	
in rheumatoid arthritis patients receiving high (10 mg) amounts of tofacitinib.
64
 Given the 561	
potential for side effects, specifically selecting patients who might be genetically predisposed to 562	
respond more favorably to tofacitinib treatment would represent a crucial advance in treating 563	
IBD and other autoimmune diseases. 564	
 In summary, our results demonstrate that tofacitinib treatment corrected barrier function 565	
and tight junction regulation in a co-culture system of IECs with PTPN2-deficient inflammatory 566	
macrophages, as well as in an in vivo model system reflecting disrupted macrophage-IEC 567	
crosstalk upon loss of Ptpn2 in macrophages, and was able to revert enhanced colitis 568	
susceptibility in mice with macrophage-specific Ptpn2 deletion. Our work integrates studies 569	
demonstrating effects of tofacitinib on macrophages alone with a major physiological role for 570	
these innate immune cells in the regulation of intestinal epithelial barrier function. Our findings 571	
indicate that tofacitinib treatment might be an especially effective treatment to restore barrier 572	
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function and maintain remission in patients harboring PTPN2 loss-of-function mutations. In 573	
addition, the presence of PTPN2 variants might be a good predictor for treatment response to 574	
tofacitinib not only in approved conditions like ulcerative colitis, but also in patients not 575	
currently indicated for treatment with tofacitinib, such as those with Crohn’s disease. Given the 576	
recent important findings demonstrating that increased intestinal permeability is significantly 577	
associated with the future risk of developing Crohn’s disease, our data make a potentially 578	
significant contribution to the discovery of new agents that can be used to prevent IBD onset by 579	
promoting and maintaining a healthy gut barrier.
26
 Since PTPN2 variants are not only associated 580	
with an increased risk to develop IBD, but also with a number of other inflammatory disorders, 581	
our findings might not only be relevant for patients suffering from intestinal inflammation, but 582	
also for patients suffering from other disease entities that are associated with PTPN2 variants in 583	
which tofacitinib represents an established therapy (e.g. rheumatoid arthritis), or where it might 584	
be considered as a therapeutic strategy in the future. 585	
  586	
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Figure 1: Tofacitinib corrects barrier defects caused by loss of PTPN2 in intestinal 768	
epithelial cells and macrophages. A) Transepithelial electrical resistance (TEER) and B) 4 kDa 769	
fluorescein-dextran (FD4) flux across Caco-2BBe monolayers pretreated with vehicle (0.5% 770	
DMSO) or tofacitinib (Tofa, 50 µM) for 1 hour prior to co-culture with control (Ctr) or PTPN2 771	
knockdown (KD) THP-1 macrophages for 24 hours. *P ≤ 0.05 cf. vehicle-treated control Caco-772	
2BBe without co-culture; #P ≤ 0.05 cf. vehicle-treated Ctr Caco-2BBe with Ctr macrophages; § 773	
P ≤ 0.05 cf. vehicle Ctr Caco-2BBe with KD macrophages, x P ≤ 0.05 cf. vehicle-treated KD 774	
Caco-2BBe  without macrophages, ¶ P ≤ 0.05 cf. vehicle-treated KD Caco-2BBe with control 775	
macrophages, o P ≤ 0.05 cf. vehicle-treated Ctr Caco-2BBe with KD macrophages; n = 3. The 776	
“−” symbol indicates no co-culture.  777	
 778	
Figure 2: Tofacitinib normalizes tight junction protein expression in Caco-2BBe cells 779	
mediated by PTPN2 loss in IECs and/or macrophages. Caco-2BBe monolayers pretreated 780	
with vehicle (0.5% DMSO) or tofacitinib (Tofa, 50 µM) for 1 hour prior to co-culture with 781	
control (Ctr) or PTPN2 knockdown (KD) THP-1 cells for 24 hours were lysed and subjected to 782	
Western blotting. A) Representative Western blot images of the indicated proteins from Caco-783	
2BBe whole cell lysates. Densitometric analyses of B) claudin-2, C) claudin-4, D) JAM-A, E) 784	
occludin, F) tricellulin, and G) TCPTP expression, all normalized to β-actin; H) Caco-2 cells 785	
were grown on cover slides and pretreated with tofacitinib before addition of conditioned 786	
medium from Ctr or KD THP-1 cells for 24 hours and subsequent immunofluorescence staining 787	
for ZO-1. Arrows point to regions with ZO-1 internalization. Scale bar: 10 µm *P ≤ 0.05, **P ≤ 788	
0.01, ****P ≤ 0.0001 cf. vehicle-treated Ctr Caco-2BBe without co-culture; #P ≤ 0.05, ##P ≤ 789	
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0.01, ###P ≤ 0.001, ####P ≤ 0.0001 cf. ; #P ≤ 0.05 cf. vehicle-treated Ctr Caco-2BBe with Ctr 790	
macrophages; § P ≤ 0.05, §§ P ≤ 0.01 cf. vehicle Ctr Caco-2BBe with KD macrophages, x P ≤ 791	
0.05 cf. vehicle-treated KD Caco-2BBe without macrophages, ¶ P ≤ 0.05 cf. vehicle-treated KD 792	
Caco-2BBe with Ctr macrophages, o P ≤ 0.05 cf. vehicle-treated Ctr Caco-2BBe with KD 793	
macrophages; n = 3. The “−” symbol indicates no co-culture. 794	
 795	
Figure 3: Functional inhibition of STAT signaling by tofacitinib in Caco-2BBe cells co-796	
cultured with macrophages. Caco-2BBe monolayers pretreated with vehicle (0.5% DMSO) or 797	
tofacitinib (Tofa, 50 µM) for 1 hour prior to co-culture with control (Ctr) or PTPN2 knockdown 798	
(KD) THP-1 cells for 24 hours. Representative Western blot images and densitometric analyses 799	
of A) phospho-STAT1 (pSTAT1) and B) phospho-STAT3 (pSTAT3) normalized to their 800	
respective total forms (tSTAT1, tSTAT3) in Caco-2BBe whole cell lysates. *P ≤ 0.05, ****P ≤ 801	
0.0001 cf. vehicle-treated Ctr Caco-2BBe without co-culture; ##P ≤ 0.01 cf. vehicle-treated Ctr 802	
Caco-2BBe with Ctr macrophages; §§ P ≤ 0.01, §§§ P ≤ 0.001 cf. vehicle Ctr Caco-2BBe with 803	
KD macrophages, xx P ≤ 0.01, xxx P ≤ 0.01 cf. vehicle-treated KD Caco-2BBe without 804	
macrophages, ¶¶ P ≤ 0.01, ¶¶¶ P ≤ 0.001 cf. vehicle-treated KD Caco-2BBe with Ctr 805	
macrophages, oo P ≤ 0.01, ooo P ≤ 0.001 cf. vehicle-treated Ctr Caco-2BBe with KD 806	
macrophages; n = 3. The “−” symbol indicates no co-culture. 807	
 808	
Figure 4: Tofacitinib reduces STAT signaling in THP-1 macrophages and cytokine IL-6 809	
secretion in co-culture studies. THP-1 macrophages co-cultured with tofacitinib-treated Caco-810	
2BBe cells for 24 hours were lysed and subjected to Western blotting. Representative Western 811	
blot images and densitometric analyses of A) phospho-JAK1 (pJAK1), B) phospho-STAT1 812	
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(pSTAT1) and C) phospho-STAT3 (pSTAT3) normalized to their respective total forms (tJAK1, 813	
tSTAT1, tSTAT3) in THP-1 whole cell lysates. D) IL-6, IL-22, and IL-10 concentrations present 814	
in the culture media after co-culture experiments, measured by ELISA. *P ≤ 0.05, *** P ≤ 0.001 815	
cf. vehicle-treated Ctr THP-1 without co-culture; § P ≤ 0.05, §§ P ≤ 0.01, §§§ P ≤ 0.001 cf. 816	
vehicle-treated Ctr THP-1 with KD Caco-2BBe, x P ≤ 0.05, xx P ≤ 0.01, xxx P ≤ 0.01 cf. 817	
vehicle-treated KD THP-1 without co-culture, ¶ P ≤ 0.05, ¶¶¶ P ≤ 0.001 cf. vehicle-treated KD 818	
THP-1 without co-culture, o P ≤ 0.05, ooo P ≤ 0.001 cf. vehicle-treated Ctr THP-1 with Ctr 819	
Caco-2BBe; n = 3. The “−” symbol indicates no co-culture. 820	
 821	
Figure 5: Tofacitinib citrate treatment reduced barrier permeability to FD4 in vivo. 822	
Intestinal permeability to creatinine, FD4, and RD70 was measured in Ptpn2
fl/fl
 and Ptpn2-823	
LysMCre mice subjected to twice daily treatment with vehicle (1% methylcellulose in PBS) or 824	
tofacitinib citrate (50 mg/kg) for 7 days. Serum concentrations of A) FD4, B) creatinine, and C) 825	
RD70 were measured 5 hours post-gavage. *P ≤ 0.05; n = 6 per group, representative results of 826	
two independent experiments. 827	
 828	
Figure 6: Aberrant tight junction protein patterns and elevated STAT3 phosphorylation in 829	
Ptpn2-LysMCre mice were reversed upon tofacitinib citrate treatment. Whole cell lysates of 830	
proximal colon IECs isolated from Ptpn2
fl/fl
 and Ptpn2-LysMCre mice treated with vehicle or 831	
tofacitinib citrate (Tofa) for 7 days were subjected to Western blot analysis. A) Representative 832	
Western blot images and respective densitometric analyses of B) claudin-2, C) claudin-4, D) 833	
JAM-A, E) occludin, F) tricellulin, normalized to β-actin. G)  Immunofluorescence staining for 834	




LysMCre mice treated with vehicle or tofacitinib citrate for 7 days. White arrows indicate cell 836	
border localization of ZO-1, green arrow cell border localization of claudin-2. See also 837	
Supplementary Figure S2. Densitometric analysis of H) phospho-STAT3 (pSTAT3) normalized 838	
to total STAT3 (tSTAT3) and I) TCPTP normalized to β-actin. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 839	
0.001; n = 6 per group, representative results of two independent experiments. 840	
 841	
Figure 7: Cytokine production and macrophage polarization are normalized by tofacitinib 842	
citrate treatment in Ptpn2-LysMCre mice. A) mRNA expression of Il6, Il10, and Il22 843	
normalized to Gapdh in whole proximal colons of mice treated with vehicle or tofacitinib citrate 844	
twice daily for 7 days. B) Protein expression of IL-6, IL-10, and IL-22 as determined by ELISA. 845	
C) Proportions of total macrophages (CD11b+, Ly6G-, F4/80+, CD64+ cells), M1 (CD86 high, 846	
CD206 low), and M2 (CD86 low, CD206 high) macrophages in whole proximal colons of mice 847	
as determined by flow cytometry (all cells were pre-gated on live, single, CD45+ cells). *P ≤ 848	
0.05, **P ≤ 0.01, ***P ≤ 0.001, **** P ≤ 0.0001; n = 6 per group, representative results of two 849	
independent experiments. 850	
 851	
Figure 8: Tofacitinib citrate treatment prevents colitis in Ptpn2-LysMCre mice. Ptpn2-852	
LysMCre and Ptpn2
fl/fl
 mice were treated twice daily with tofacitinib citrate starting 3 days 853	
before exposure to 1.5% DSS in the drinking water for 7 days. A) FD4 permeability at the start 854	
of the experiment (d-3), at the day of DSS start (d0) and at the end of the experiment (d7). B) 855	
Weight development, C) disease activity score, D) colon length, E) representative pictures from 856	
H&E stained terminal colon sections, and F) respective histological scoring of colitis severity. 857	
Scale bars: 100 µm. *P ≤ 0.05, **P ≤ 0.01; n = 4 per group.   858	
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Supplementary Figure 1: Tofacitinib partially reduces pro-inflammatory cytokine TNF-α 859	
secretion in co-culture studies. TNF-α levels present in the culture media after co-culture 860	
experiments as measured by ELISA. *P ≤ 0.05, *** P ≤ 0.001 cf. untreated Ctr THP-1; #P ≤ 861	
0.05, ##P ≤ 0.01 cf. vehicle-treated THP-1; n = 3. 862	
 863	
Supplementary Figure 2: Tofacitinib citrate treatment reduces claudin-2 expression in  864	
Ptpn2-LysMCre mice and normalizes localization of ZO-1 to the cell membrane. 865	
Immunofluorescence staining for ZO-1, E-cadherin, and claudin-2 on colon sections from 866	
Ptpn2
fl/fl
 and Ptpn2-LysMCre mice treated with vehicle or tofacitinib citrate for 7 days. White 867	
squares indicate pictures shown in main Figure 6G. 868	
 869	
 870	
Supplementary Figure 3: Tofacitinib does not affect STAT1 phosphorylation in IECs from 871	
Ptpn2-LysMCre mice in vivo. Lysates of proximal colon IECs isolated from Ptpn2
fl/fl
 and 872	
Ptpn2-LysMCre mice treated with vehicle or tofacitinib citrate were analyzed for STAT1 873	
phosphorylation by Western blot. n = 6 per group, representative results for one of two 874	




Supplementary Table 1: Primary and secondary antibodies for Western blotting 878	
Antibody Host Provider Catalog No. Dilution 
Claudin-2 Mouse Thermo Fisher Scientific (Rockford, IL) 32-5600 1:1000 
Claudin-4 Mouse Invitrogen (Camarillo, CA) 32-9400 1:1000 
JAM-A Rabbit Invitrogen (Camarillo, CA) 36-1700 1:1000 
Occludin Rabbit Thermo Fisher Scientific (Rockford, IL) 71-1500 1:1000 
Tricellulin 
(MARVELD2) 
Rabbit Abcam ab203567 1:1000 
TCPTP  
(anti-mouse) 
Mouse Medimabs (Quebec, Canada) MM-0018 1:500 
TCPTP 
(anti-human) 
Mouse EMD Millipore (San Diego, CA) PH03L 1:500 
Phospho-JAK1 
(Tyr 1022/1023) 
Rabbit Cell Signaling Technology (Danvers, MA) #3331 1:1000 
Total JAK1 Rabbit Cell Signaling Technology (Danvers, MA) #3344 1:1000 
Phospho-STAT1 
(Tyr 701) 
Rabbit Cell Signaling Technology (Danvers, MA) #9167 1:1000 
Total STAT1 Rabbit Cell Signaling Technology (Danvers, MA) #9175 1:1000 
Phospho-STAT3 
(Tyr 705) 
Rabbit Cell Signaling Technology (Danvers, MA) #9145 1:1000 
Total STAT3 Mouse Cell Signaling Technology (Danvers, MA) #9139 1:2000 




Jackson Immunoresearch Laboratories, 





Jackson Immunoresearch Laboratories, 
Inc. (West Grove, PA) 
#115-036-062 1:3000 
 879	




Provider Catalog No. Clone Dilution 
CD11b (mouse) BV605 Rat IgG2b κ Biolegend 101237 M1/70 1:200 
Ly-6G (mouse) BV510 Rat IgG2a κ Biolegend 127633 1A8 1:100 
Ly-6C (mouse) PerCP/Cy5.5 Rat IgG2c κ BioLegend 128011 HK1.4 1:200 
CD11c (mouse) PE/Cy7 Hms IgG Biolegend 117318 N418 1:200 
MHC-II (mouse) AF700 Rat IgG2b κ 
Thermo 
Fisher 
56-5321-80 M5/114.15.2 1:100 
CD64 (mouse) PE Ms IgG1 κ BioLegend 139303 X54-5/7.1 1:200 
CD45 (mouse) PB Rat IgG2b κ BioLegend 103125 30-F11 1:400 
F4/80 (mouse) APC Rat IgG2a κ BioLegend 123115 BM8 1:200 
CD3 (mouse) BV650 Rat IgG2b κ Biolegend 100229 17A2 1:400 
NK-1.1 (mouse) BV650 Ms IgG2a κ BioLegend 108735 PK136 1:200 
CD45R/B220 
(mouse/human) 
PE/Cy5 Rat IgG2a κ Biolegend 103209 RA3-6B2 1:400 
CD206 (mouse) PE Rat IgG2a κ Biolegend 141705 C068C2 1:100 






130-092-575 several 1:100 
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Supplementary Table 3: Primer sequences used for quantitative PCR 882	
Primers Forward Reverse 
















































































-	 Ctr	 KD	 -	 Ctr	 KD	
Vehicle	 Tofa	
-	 Ctr	 KD	 THP-1	 -	 Ctr	 KD	
Vehicle	 Tofa	
-	 Ctr	 KD	 -	 Ctr	 KD	
Vehicle	 Tofa	
























































































































































































THP-1	-	 Ctr	 KD	 -	 Ctr	 KD	 -	 Ctr	 KD	 -	 Ctr	 KD	





Ctr	Caco-2BBe	 KD	Caco-2BBe	 Ctr	Caco-2BBe	 KD	Caco-2BBe	





































































THP-1	-	 Ctr	 KD	 -	 Ctr	 KD	 -	 Ctr	 KD	 -	 Ctr	 KD	












































THP-1	-	 Ctr	 KD	 -	 Ctr	 KD	 -	 Ctr	 KD	 -	 Ctr	 KD	





























































-	 Ctr	KD	 -	 Ctr	KD	
Vehicle	 Tofa	
-	 Ctr	KD	 THP-1	-	 Ctr	 KD	
Vehicle	 Tofa	
-	 Ctr	 KD	 -	 Ctr	 KD	
Vehicle	 Tofa	
































Caco-2BBe	-	 Ctr	 KD	 -	 Ctr	 KD	 -	 Ctr	 KD	 -	 Ctr	 KD	

































































































































































Caco-2BBe	-	 Ctr	 KD	 -	 Ctr	 KD	 -	 Ctr	 KD	 -	 Ctr	 KD	
Vehicle	 Tofa	 Vehicle	 Tofa	
Caco-2BBe	-	 Ctr	KD	 -	 Ctr	 KD	 -	 Ctr	 KD	 -	 Ctr	 KD	
Vehicle	 Tofa	 Vehicle	 Tofa	
-	 Ctr	 KD	
Vehicle	 Tofa	
-	 Ctr	 KD	 -	 Ctr	 KD	
Vehicle	 Tofa	
-	 Ctr	KD	 Caco-2BBe	 -	 Ctr	 KD	
Vehicle	 Tofa	





-	 Ctr	 KD	 -	 Ctr	 KD	
Vehicle	 Tofa	
-	 Ctr	 KD	 Caco-2BBe	 -	 Ctr	 KD	
Vehicle	 Tofa	
-	 Ctr	 KD	 -	 Ctr	 KD	
Vehicle	 Tofa	
-	 Ctr	 KD	 Caco-2BBe	 -	 Ctr	 KD	
Vehicle	 Tofa	
-	 Ctr	 KD	 -	 Ctr	 KD	
Vehicle	 Tofa	













































































































































































































































































































































































































































































































































































































































































Vehicle	 Tofa	 Vehicle	 Tofa	
pSTAT1	
(84,91kDa)	
tSTAT1	
(84,91kDa)	
β-acCn	
(42kDa)	
β-acCn	
(42kDa)	
0
1
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1
/t
S
T
A
T
1
Ptpn2fl/fl	Vehicle	
Ptpn2fl/fl	Tofa	
Ptpn2-LysMCre	Vehicle	
Ptpn2-LysMCre	Tofa	
Ptpn2fl/fl	 Ptpn2-LysMCre	
